Pleurodesis with pseudomonas aeruginosa-mannose–sensitive hemagglutinin for pneumothorax secondary to COPD: a retrospective study by unknown
RESEARCH Open Access
Pleurodesis with pseudomonas aeruginosa-
mannose–sensitive hemagglutinin for
pneumothorax secondary to COPD:
a retrospective study
Hansheng Wu1*, Dongling Luo1, Patrick Y. Tan2, Weisheng Wang1 and Shaobo Zhang1
Abstract
Background: Pneumothorax is a potentially life-threatening complication of chronic obstructive pulmonary disease
(COPD) that leads to cardiopulmonary compromise. According to the British Thoracic Society (BTS) guidelines,
medical pleurodesis is recommended for inoperable patients suffering from COPD-related pneumothorax. Several
sclerosing agents are currently in use, but none have been proven to be the best choice, as each one has
effectiveness and safety issues. Recent research has shown that Pseudomonas aeruginosa-mannose–sensitive
hemagglutinin (PAMSHA) is a safe bioagent with low toxicity and good immune-boosting effects that can induce
the aseptic inflammation necessary to cause pleural adhesion.
The aim of this study is to report our experience using PAMSHA in medical pleurodesis to treat inoperable cases of
persistent pneumothorax secondary to COPD.
Methods: Records of 78 inoperable patients with persistent pneumothorax secondary to COPD treated with
PAMSHA pleurodesis were retrospectively reviewed. Pleurodesis was performed by administering 1 ml of PAMSHA
(mixed with lidocaine and 30-40 ml of normal saline) intrapleurally.
Results: The resolution of pneumothorax was observed in all of the patients treated with PAMSHA pleurodesis
(success rate = 100%). Some of them experienced mild chest pain and fever, but no long-term side effects were
reported.
Conclusion: Our data suggest that PAMSHA pleurodesis is a safe and effective option for the treatment of
persistent pneumothorax secondary to COPD.
Keywords: PAMSHA, Intrapleral injection, Chronic obstructive pulmonary disease, Secondary spontaneous
pneumothorax
Background
Secondary spontaneous pneumothorax (SSP) occurs as a
complication of certain lung diseases, the most common of
which is chronic obstructive pulmonary disease (COPD).
Approximately 50-70% of SSP cases are attributed to
COPD [1–4], and SSP in COPD occurs when subpleural
bullae form and eventually rupture. This leads to persistent
air leakage into the chest and worsens the symptoms of
dyspnea already caused by COPD. According to the
British Thoracic Society (BTS) guidelines, the manage-
ment of SSP includes oxygen supplementation, the
insertion of a chest drain, and active intervention by
thoracic surgery. However, among patients with SSP who
are unfit for surgery, medical pleurodesis is offered as an
appropriate alternative [5]. Despite the attractiveness of
this non-surgical approach, its indication and the selection
of the sclerosing agents used for the procedure are still
debated, and the results are poorly defined.
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To help shed more light on this matter, we present
our study of the use of Pseudomonas aeruginosa-
mannose–sensitive hemagglutinin (PAMSHA) for the
pleurodesis of patients with pneumothorax secondary to
COPD. We hope that this report will add knowledge of
the ways in which SSP is treated.
Methods
Study design and ethics board approval
Records of patients who underwent PAMSHA pleurodesis
at our hospital’s surgical ward from January 2011 to
December 2013 were retrieved for the purpose of
reviewing the effects of this intervention. The interven-
tions were performed due to an increasing number of
recurrent COPD-related pneumothorax cases in the
surgery ward of our hospital. After a discussion with
colleagues, our surgical team decided to investigate the
efficacy and safety of the agent PAMSHA for pleurodesis
of these affected patients. With the approval of the depart-
ment chair and the ethics board/committee of the hospital
(The First Affiliated Hospital of Shantou University
Medical College Ethics Review Form – Science Research
-No. 2015075), we invited patients who had suffered from
COPD-related pneumothorax with persistent air leaks for
two weeks to enroll in our intervention. According to the
enrollment criteria, these patients must have already re-
ceived treatment for two weeks consisting of the following:
thoracostomy tube placement at the time of admission,
guideline-recommended antibiotics for their specific con-
ditions, patient-specific cardiopulmonary and nutritional
support, and oxygen supplementation. After discussion of
the risks and benefits of the procedure, those who enrolled
were asked to sign an informed consent form.
Reagents used
The PAMSHA used was from the Beijing Wanter Bio-
pharmaceutical Company Ltd (Beijing, China). It was in
liquid form and packaged as 1.0 ml of solution per am-
pule. For our intervention, we added 1.0 ml of PAMSHA
to a mixture of 50 ml of lidocaine (5 ml/0.1 g) and 30-
40 ml of 0.9% NaCl saline solution. All of the mixture
was used in each administration.
Procedure of administration and monitoring
Skin testing for hypersensitivity was performed prior to
intrapleural administration of the agent. After skin test-
ing, the sclerosing agent was prepared for administration
(aseptic procedures included). With the patient in the
supine position, the tube was clamped 10 cm away from
the chest wall. The sclerosing agent was then injected
5-6 cm proximal to the clamped end, and the puncture
site was sealed with adhesive plaster. To evenly distribute
the sclerosing agent, each patient was asked to change
position in various ways - from left decubitus to right
decubitus, from supine to prone position, and with the
head and upper chest elevated. The patient assumed each
position for 15 min, and the thoracostomy tube was moni-
tored throughout all position changes. As it was possible to
aggravate the pneumothorax throughout the procedures
due to insufficient drainage of air, all patients were observed
and monitored for cardiorespiratory problems. The tube
was unclamped and reclamped every 6-8 h post-injection
to monitor for air leakage. For patients who did not report
severe adverse effects like chest pain and fever after the first
injection, repeated injections of 2 ml of PAMSHA (mixed
with 30-40 ml of 0.9% NaCl and 5 ml of lidocaine) were ad-
ministered on alternate days (3rd, 5th, etc.) until signs of air
leakage were no longer observed in the water-sealed con-
tainer. If severe adverse effects occurred, a standby support-
ive therapy plan was put in place, and the repetition of the
injections was postponed to 4 to 5 days after. The patients
were monitored for improvement through clinical assess-
ments (interviews, self-reports, and physical exams) and
imaging studies (chest x-rays), and it was expected that air
leakage would not be observed after 3 injections.
Results
A total of 78 patient records were retrieved, and the
patients enrolled in the intervention were between 45
and 89 years of age, with an average age of 58 years. In
total, 76 were males, and 2 were females. They were all
heavy smokers who had typical symptoms and signs of
COPD such as persistent productive cough, decreased
chest excursion, absent fremitus, hyperresonance, and
diminished breath sounds. They were determined to
have poor pulmonary function and deemed inoperable
according to different tests (Table 1). Their chest x–rays
and CT scans showed pneumothorax, diffuse emphysema,
and subpleural bullae. Complications were also noted in
these patients. Among them, 15 had bronchiectasis; 35
had latent tuberculosis (TB) infections; 22 had mild
abnormalities of liver and kidney function; 16 had
Table 1 Results of the selected diagnostic tests
Clinical parameters Frequency
[Percentage (n)]
Hypercarbia (PaCO2 > 45 mmHg)
and hypoxemia (PaO2 < 55 mmHg)
based on arterial blood gas analysis
82% (64)
VC < 1 L (<50% of the predicted value),
FEV1 < 0.5 L (<40% of the predicted value),
MVV < 50% of the predicted value,
FEV1/VC <0.7 in pulmonary function tests
98% (76)
Confirmed pneumothorax with diffuse
emphysema and subpleural bullae from
CT or chest X-ray
100% (78)
Breath-holding test < 15 s 95% (74)
Abbreviations: FEV1 Forced expiratory volume in one second, MVV maximal
voluntary ventilation, VC vital capacity
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ischemic heart diseases with pulmonary P waves on ECG;
and 73 had elevated white blood cell counts.
All of the patients had undergone thoracostomy tube
placement at the time of their admission, and they had also
been provided with other supportive measures such as oxy-
gen supplementation, cardiopulmonary stabilization, and
infection control using guideline-recommended antibiotics.
After two weeks of standard treatment, the patients
with persistent air leakage were administered injections
of the PAMSHA mixture. Excluding the lidocaine and
saline mixture, the average volume of PAMSHA used for
each patient was 5 ml (administered over a period of 7
to 9 days). To reduce recurrence, another 2 ml of
PAMSHA (together with the lidocaine and normal saline
mixture) was injected. (This was still administered despite
the resolution of the pneumothorax on imaging studies.)
The frequency of administration was based on the clinical
assessments (symptoms and physical examinations) and
the results of the chest x-rays. After pleurodesis, x-ray and
CT scans of the chest were requested, and these showed
the re-expansion of the affected sides (Figs. 1 and 2). We
considered this to be a sign of the resolution of the
pneumothorax. These radiographic results were supported
by the improvement of the respiratory symptoms in the
patients. Based on the physical examination, it was further
noted that the hyperresonant sounds were reduced, and
the breath sounds improved. During this period, 51
patients experienced mild but transient chest pain and
fever, and 3 complained of severe chest pain and dyspnea
(Table 2). These patients were given oxygen supplementa-
tion, intravenous steroid injections, and oral indomethacin,
and they reported the improvement of their symptoms.
Adverse effects such as appetite changes, renal failure, and
liver impairment were not reported. After a year of follow-
up, none of the participants reported being readmitted for
a pneumothorax, and none of them were reported to have
died from any cause.
Discussion
COPD is a severe lung disease characterized by persistent
airflow limitation that progresses over time. In China, it
has a prevalence rate of 8.2% in those over 40 years of age.
Diffuse emphysema and subpleural bullae are often found
on chest x-rays, and these bullae are the main causes of
persistent air leakage, which is difficult to treat. Once air
leakage occurs, it devastates the patients because their
baseline lung function becomes more limited, and it
pushes them to undergo a surgical procedure under
general anesthesia [2]. The post-operative complica-
tions could also jeopardize their general condition, so
the management of pneumothorax secondary to COPD
is complicated. Furthermore, patients with this condi-
tion could suffer from pneumonia and respiratory failure
after lung volume reduction surgery, making it difficult for
them to be weaned from ventilators.
The main objective of management of patients with
COPD complicated by pneumothorax is to stop air leaks
using relatively simple and safe methods, and various
methods have been used to meet this objective. If a patient
is still in good condition and an operation is tolerable, sur-
gical removal of the subpleural bullae is considered the
first line treatment. This prevents the enlarging bullae
from gradually compressing the normal lung tissues.
However, surgical intervention appears to be a radical
Fig. 1 Chest x-rays of one of our patients before and after PAMSHA therapy. This was a 67-year-old man who was admitted to our hospital for
sudden dyspnea for one day. Based on detailed history collection and ancillary tests, COPD was confirmed. The picture on the left is the initial
chest X-ray showing severe pneumothorax affecting half of his left lung. After two weeks of hospitalization, PAMSHA was injected intrapleurally.
The picture on the right is the chest X-ray from 1 week after PAMSHA injection. It shows the complete removal of the gas and re-expansion of
the lung. This confirmed the effectiveness of the method, and no severe adverse effects were reported in this patient
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method for recurrent pneumothorax, and there are pa-
tients who cannot undergo such a procedure. The manage-
ment of COPD-related pneumothorax by bronchial
occlusion in combination with talc powder has been
reported to be successful in three cases [6]. Though no
recurrences were observed for more than 1 year, the long
hospitalization and complex procedure associated with it
made it less favorable. Tube thoracostomy is effective in
providing symptomatic improvement, but when it is
repeated, it can be a physical and emotional burden to the
patients. Another method is to rub the pleural membranes
during surgical intervention, which leads to pleural adhe-
sion and prevents the recurrence of pneumothorax.
According to the BTS guidelines, medical pleurodesis
remains the first choice for treating persistent air leakage
[5], as it is safe and easy to perform. It induces pleural
adhesion through aseptic inflammation and is indicated for
patients with near-normal pulmonary function and no ob-
vious bullae on CT imaging. However, the use of this
method has problems, as there is no consensus yet on the
best technique to follow. Additionally, the sclerosing agents
used for this procedure have variable efficacy and safety.
A recent meta-analysis confirmed the superiority of
talc as a sclerosing agent. Talc use can induce intense
intrapleural inflammation by producing numerous pro-
fibrotic factors that cause adhesions and fibrosis be-
tween the pleural membranes [7]. Common side effects
of talc include fever (10-17%), pain, and gastrointestinal
symptoms. Less common side effects include arrhythmia,
dyspnea, respiratory failure, a systemic inflammatory
response, empyema, and the dissemination of talc to
other regions [8–10]. However, talc particles and other
pro-fibrotic factors hypothetically have the potential to
be absorbed and lead to systemic inflammation. This
problem has raised questions about the safety of talc as
a sclerosing agent [10]. Therefore, scientists are still
searching for the most suitable sclerosing agent for
pleurodesis – one that could yield a high success rate
with a low risk of severe adverse reactions.
Mannose-binding hemagglutinins in extracts of
Pseudomonas aeruginosa were first proposed in 1977
and have now gained more consideration because of
their anti-tumor effects [11]. Pseudomonas aeruginosa-
mannose-sensitive hemagglutinin (PAMSHA) is a perit-
richous P. aeruginosa strain with MSHA fimbriae that
can inhibit activation of the epidermal growth factor
receptor signaling pathway in tumor cells [12]. Animal
studies have shown that PAMSHA affects both the pro-
inflammatory and anti-inflammatory processes, which
help limit the severe adverse reactions caused by sys-
temic inflammation [13]. In other studies, it has been
reported to induce apoptosis in tumor cells and improve
immune function, which can prevent metastasis and the
recurrence of certain types of cancer [14–19]. It has also
been used to treat malignant pleural effusion [20–22].
Fig. 2 CT scans of one of our patients before and after PAMSHA therapy. This was a 61-year-old man who presented with shortness of breath
and a history of COPD. His initial chest CT (image on the left) showed a lot of free gas in the pleural space and bullae in the left side of the lung.
General support, including oxygenation and antimicrobials, was provided to this patient before PAMSHA pleurodesis, and 5 days after PAMSHA
injection, his breathing improved. A repeat chest CT scan was performed that showed the disappearance of the free gas in his chest and
full re-expansion of the previously compressed lung (right image)
Table 2 Incidence of main short-term side effects
Complications / Intervention Patients (78)
[Percentage (n)]
Fever only (<38.5 °C) / observation 28.2% (22)
Mild chest paint only / given oral indomethacin 23.7% (18)
Fever (>38.5 °C) and chest pain / oxygen
uptake, oral indomethacin
14.1% (11)
Severe chest pain and dyspnea / oxygen
uptake, intravenous steroid injections,
and oral indomethacin
3.8% (3)
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In this study, we report our experience performing
pleurodesis using PAMSHA as the sclerosing agent. We
think that this method is more convenient than bron-
chial occlusion followed by the addition of talc powder.
Medical pleurodesis with PAMSHA can produce similar
results but without the risk of severe side effects and the
trouble of doing a multi-step procedure. After observing
the effects of the intrapleural administration of PAM-
SHA in 78 inoperable cases of pneumothorax secondary
to COPD, our follow-up imaging studies showed signs of
resolution of the pneumothorax. After a year of follow-
up, none of our patients reported readmission due to
recurrence of a pneumothorax. For us, this is enough
information to report that we had a success rate of 100%
for the procedure. Additionally, adverse effects such as
chest pain and low-grade fever were only transient and
resolved well with supportive care. No gastrointestinal
and neurologic dysfunction, bone marrow inhibition, or
liver/kidney impairment were reported.
There are limitations to this study. First, this study
was retrospective, and there was no standardized evalu-
ation of the inoperability of the patients from the per-
spective of pulmonary function. Second, the reporting of
adverse effects after pleurodesis was relatively subjective
and did not employ standardized scoring systems to
quantify clinical improvement properly. We believe that
a prospective study with precise definitions of the vari-
ables and a standardized treatment protocol will be help-
ful in validating our results.
Conclusion
Pleurodesis is an appropriate treatment for pneumothorax
secondary to COPD. However, choosing a highly effective
and safe sclerosing agent for this procedure is still contro-
versial. Clinician preferences, agent characteristics (effi-
cacy and safety), and commercial availability are factors
that contribute to the selection of a sclerosing agent.
Given the success rate and minimal amount of minor
complications reported, we conclude that PAMSHA is
an effective and safe sclerosing agent that can be used to
treat patients who have pneumothorax secondary to
COPD. However, further studies are needed to confirm
our conclusion.
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